The Company continues to expect total revenue for the fiscal year ended December 31, 2024, to approximate $595 million, reflecting growth of approximately 23% compared to 2023. This includes surgical revenue of $530 million and approximately $65 million of EOS revenue. The Company expects full year 2024 non-GAAP adjusted EBITDA to approximate $22 million, which implies 560 basis points of improvement in adjusted EBITDA margin compared to full year 2023. Under the prior non-GAAP financial definition, adjusted EBITDA guidance would have approximated $40 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATEC:
- Alphatec (ATEC) Q4 Earnings Cheat Sheet
- PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls
- Alphatec initiated with an Overweight at Wells Fargo
- Aclarion plans to launch CLARITY trial, provides update on Alphatec partnership
- Alphatec price target raised to $25 from $22 at Canaccord
